anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is an acute intervention study to compare the health benefits, in relation to changes in postprandial glucose and cognitive performance, of consumption of 3 soft fruits, raspberries, cherries, and honeyberries. It will have a randomised controlled crossover design where the volunteers will return for 4 stand-alone study sessions. All study procedures will be carried out at the Human Nutrition Unit (HNU) of the Rowett Institute. . The first study session will be an oral glucose tolerance test (OGTT). The glucose load for the OGTT in all sessions will be given as carbohydrate meal consisting of white bread, spread, low-polyphenol jam. (meal: 75g carbohydrate total). The remaining three will be intervention sessions which will be identical in all respects except for the addition of either honeyberry, cherry, or raspberry. There will be a minimum of 1 week washout period.
An automated method and system for discriminating between normal lungs and abnormal lungs having interstitial disease and/or septal lines, wherein a large number of adjacent regions of interest (ROIs) are selected, corresponding to an area on a digital image of a patient's lungs. The ROIs each contain a number of square or rectangular pixel arrays and are selected to sequentially fill in the total selected area of the lungs to be analyzed. A background trend is removed from each individual ROI and the ROIs are then analyzed to determine those exhibiting sharp edges, i.e., high edge gradients. A percentage of these sharp-edged ROIs are removed from the original sample based on the edge gradient analysis, a majority of which correspond to rib-edge containing ROIs. After removal of the sharp-edged ROIs, texture measurements are taken on the remaining sample in order to compare such data with predetermined data for normal and abnormal lungs. Thus, a computerized scheme for quantitative analysis of interstitial lung diseases and/or septal lines appearing in digitized chest radiographs can be implemented in practical clinical situations.
Subjects enrolled in this arm of the study will receive a 50mg/m2 bolus of Hydrocortisone after successful completion of CPB and the post-pump ACTH stim test has been performed. This will be followed by a continuous infusion of Hydrocortisone that will be tapered over the next 120 hours.
The study will determine whether oxytocin (OT) administration 30 min before a training session enhances the learning of social information in the context of a social cognitive skills training (SCST) program, and it will test a possible mediator of this effect. Subjects with psychotic disorders will be randomized to one of four groups in a 2 by 2 factorial design: OT with SCST; Placebo with SCST; OT with training control condition; placebo with training control condition. Target engagement will be measured in an OT challenge (placebo versus OT one week apart) prior to baseline assessment. The measure of target engagement will be EEG mu suppression while observing biological motion. A social cognition battery will be administered at baseline, at midpoint after 6 weeks of SCST, and at completion of training at 12 weeks. The battery will include measures of social cue identification and mentalizing.
The invention discloses a method for forming a fungi fermentation product containing N-acetylglucosamine. The fungi fermentation product containing N-acetylglucosamine can convert cancer cells into normal cells through a mesenchymal epithelial transition mechanism. The method uses fungi as a starting material which together with a  Cordyceps -related fungus is fermented to form a fermentation product which induces a mesenchymal epithelial transition to convert cancer cells into normal cells. The fungi cell wall contains chitin. The fermentation liquid is produced by fermentation of  Cordyceps  with chitin as the substrate. The main product is N-acetylglucosamine confirmed by an HPLC analysis. According to the experimental data, the fermentation product of N-acetylglucosamine converts cancer cells into epithelial cells that contain E-cadherin and has a square shape. Thus, it is proved that the fermented substance converts cancer cells into normal cells through induction of the mesenchymal epithelial transition mechanism.
BACKGROUND: Age-related hearing loss (ARHL) - also termed presbycusis - is prevalent among older adults, leading to a range of issues. Although considerable progress in the understanding of ARHL over the decades, available reports lack data from recent years and do not comprehensively reflect the latest advancements and trends. Therefore, our study sought to assess research hotspots and trends in ARHL over the past 5 years to provide the basis for future research.
MATERIALS AND METHODS: The Web of Science Core Collection database was searched and screened from January 1, 2019 to October 21, 2023, according to the inclusion criteria. CiteSpace (5.8.R3), VOSviewer (1.6.19), and Microsoft Excel 2019 were employed for bibliometric analysis and visualization.
RESULTS: 3084 articles from 92 countries led by the United States and China were included. There has been a steady upward trend in the number of publications from 2019 to 2023. The most productive institutions, authors, and journals are Johns Hopkins University (n = 113), Lin FR (n = 66), and Ear and Hearing (n = 135), respectively. Trend topic analyses revealed that "cochlear synaptopathy" and "dementia" were the predominant foci. Keywords, including "individuals" and "national health", began to appear.
CONCLUSION: Over the past 5 years, the annual number of publications has increased significantly and will continue to do so. Research on the mechanism of ARHL, represented by "oxidative stress", is a continuing focus. Emerging topics such as "individual differences" and "national health" may be potential future hotspots in this field.
PURPOSE: To obtain a skin cosmetic capable of effectively suppressing the formation of wrinkles and pigmentation by using a specific hydroxybenzoic acid derivative or its salt. CONSTITUTION: This skin cosmetic comprises a hydroxybenzoic acid derivative of formula I [R<1> is H or an alkyl which may have OH; R<2> is H or an alkyl or an acyl which may have OH; X is CH2 CH2 , CH=CH, CH=N, CH2 -NH, N=CH or NH-CH2 ; (n) is 0-5] or its salt. For example, compounds of formulas II to IV are cited as the compound of formula I. The compound of formula I in an amount of 0.001-20wt.% expressed in terms of the solid matter is preferably blended in the dermal cosmetic. The cosmetic is especially effectively used for treating wrinkles and pigmentation caused by irradiation of ultraviolet ray.  The cosmetic can be improved in its suppressing effects on the formation of wrinkles and dermal stains by adding an antiinflammatory agent, an antioxidant, etc., such as allantoin, a vitamin E derivative, glycyrrhizin or an ascorbic acid derivative in addition to the essential ingredient.
Advanced glycation end products (AGEs) are a heterogenous group of compounds form mainly by the Maillard reaction. AGEs can be found endogenously and in some foods. Several AGEs have been characterized, but carboxymethyl-lysine (CML) is one of the most widely studied in foods. Several studies have demonstrated the association between advanced glycation end products and several pathologies. However, few studies have focused on studying the absorption and excretion processes of these glycation products. Therefore, the objective of the study is to evaluate the effect of carboxymethyl-lysine (CML) on the levels of absorption and excretion of CML, and in the microbiota of healthy adults. To achieve the objective, a randomized clinical trial will be carried out, which will consist of a 7-day washout period during which participants will receive general recommendations that allow them to stick to a diet with a low CML content, adherence to these recommendations will be evaluated through three dietary records. At the end of the washing period, participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days. Participants will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention, these preparations will be elaborated by a catering company with indications and supervision by the research group. Participants will assist to the research center to receive the breakfast, lunch and snacks. After lunch the subjects will receive a package containing a snack for mid-evening and the dinner. Adherence to the diet during the intervention period will be evaluated through a dietary record of foods.

The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat.

The diet with high content of CML will have twice the amount that the low diet, but with similar amounts of macro and micronutrients.

A blood sample will be taken on the first day of the intervention to measure CML basal levels. In order to evaluate the levels of CML absorption, the serum collection will be performed on the second day and at the end of the intervention. To evaluate the levels of CML excretion 24-hours urine will be collected the day before the intervention and the day after the dietary intervention finished. To evaluate the effects on the microbiota subjects will take a fecal sample the day before and a day after the intervention. Measurement of CML in serum, 24-hour urine and food will be performed by Liquid chromatography tandem-mass spectrometry. DNA extraction from the fecal sample will be carried out by a commercial kit. Bacterial log10 number of copies will be determined by using q-PCR.
PURPOSE:To obtain an artificial liver-like tissue secreting collagen, lypocyte and bile-relating substance, by culturing a parenchymatous cell of liver in a medium containing a specific factor and insulin. CONSTITUTION:A parenchymatous cell separated from a warm-blooded animal is cultured in a medium containing insulin and a cell-proliferation factor produced from the serum obtained from the homogenate of the intestinal mucosa of a warm-blooded animal (e.g. rat, mouse, etc.) or from the serum obtained from the blood of a warm-blooded animal having damaged liver, to obtain the objective artificial liver-like tissue. The tissue contains arranged liver cells contacting closely with each other, has gaps corresponding to the capillary bile ducts and secrets collagen, lipocyte and bile-relating substance. The liver- like tissue is useful for the in vitro test of liver function and pharmacological test. It is applicable also as a substitute for artificial liver in clinical therapy.
The incidence of geriatric hip fractures is projected to increase by more than 250% in the next twenty-five years as the world population ages. Hip fracture in elderly patients are associated with significant morbidity and mortality. One of the significant morbidity is blood loss, which has been reported as high as 1500ml. Blood loss may lead subsequent blood transfusion. The rate of blood transfusion has been reported between 20 to 60%. Blood loss and subsequent blood transfusion could lengthen the overall hospital length of stay and delay the rehabilitation.

Tranexamic acid, one of antifibrinolytic agents, is a synthetic derivative of the amino acid lysine and acts as a competitive inhibitor in the activation of plasminogen to plasmin, therefore preventing the degradation of fibrin. Shakur et al. reported that the use could reduce mortality in trauma patients. Tranexamic acid has been widely used in elective orthopaedic surgery such as total joint replacement and spine surgery. Several authors reported that tranexamic acid could decreases the blood loss, transfusion rate and cost.
The invention relates to inhaled quercetin nanometer-particles. The inhaled quercetin nanometer-particles comprise 1-5 parts of quercetin, 1-20 parts of chitosan or derivative of the chitosan, 1-10 parts of phospholipid or a derivative of the phospholipid and 1-10 parts of excipient. The chitosan or the derivative of the chitosan is one or more of chitosan, chitosan oligosaccharide, quaternary ammonium salt of chitosan and carboxymethyl chitosan at high molecular weight, mediate molecular weight and low molecular weight. The diameter of each inhaled quercetin nanometer-particle ranges from 100 nanometers to 0.49 micrometer. The quercetin is prepared into a powder slow-release nanometer-particle inhalant and directly plays a role in the lungs, so that the defects that the quercetin is not soluble in water, absorption of the quercetin is difficult, and the quercetin is prone to oxidization are overcome, the bioavailability of the quercetin is improved, slow release can reduce a dosage, and the problems that a patient is poor in compliance, no specific treating medicine for radioactive damage is provided are solved by inhalation. The inhaled quercetin nanometer-particles have the power characteristics of the appropriate diameter, the appropriate form and like and has the slow release property. A preparation method of the quercetin nanometer-particles breathed into the lungs has the advantages of being easy and convenient to operate, stable in technology, capable of enabling industrial production to be easily achieved and the like.
Participants receive an 8-week waitlist condition with some attentional-control via monitoring for clinical deterioration. After a post-waitlist assessment, participants in this condition are offered the Brief Transiagnostic GCBT for eight weeks.
Major colorectal surgery, i.e. surgery involving a wide colon resection and/or a very low anastomosis, remains problematic, despite great advances in medico-pharmaceutical treatment, improvement in surgical techniques, and sophisticated postoperative management. Such surgery is still accompanied by an unacceptably high morbidity of 15% to 23.2% leading to an increase in the number of ventilatory support days, prolongation of total hospital stay, significantly higher medical costs, patient suffering, and, unfortunately mortality. Worse than this, nowadays, infections and sepsis are by far the most common morbidities, either as initial cause or as a consequence of another complication, such as anastomotic leakage. Ongoing clinical studies have reported probiotic therapies to be beneficial in elective surgery cases, since they have been shown to successfully modulate the GI flora in a plethora of medical settings and in critically ill and trauma patients. More precisely, recent randomized controlled studies and meta-analyses in elective surgery and abdominal surgery patients have demonstrated that the perioperative use of probiotics is safe and reduces both the incidence of postoperative wound infections, sepsis, post-operative pneumonia and other infections, and the necessary duration of hospital stay and length of antibiotic therapy. However, there exist few controlled, large-scale, trials comparing the current standard treatment with the probiotic concept and showing the superiority of the latter in colonic surgery with regard to a reduced complication rate. Therefore, the investigators decided to conduct a randomized controlled trial to investigate the impact of a probiotics treatment protocol on postoperative morbidity in an open elective colonic surgery cohort. The major objective is to evidence a reduction in 30-day infectious, surgery-related morbidity: any surgical site infection; organ specific infections; systemic infections and anastomotic leakage. Minor objectives related to the reduction in other non-infectious complications, as well as the assessment of outcome indicators such as the number of days in postoperative ileus, on mechanical ventilation, stay in ICU, total hospitalization and mortality in the 30-day post-operative period.
The present invention is directed to novel compounds, methods of manufacture and methods of use. The present invention is also directed to solid drug/active agent particles having one or more of the compounds of the present invention associated with the surface thereof. The compounds of the present invention are comprised of a non-polar polyether covalently linked to an anionic sulfonate group. The compounds have an amphipathic quality and preferably, are surface active. Such compounds are preferably useful as surface-active agents to coat and stabilize dispersions of particles in a continuous liquid medium. These surface-active agents may be applied in the stabilization of suspensions, emulsions, or liposome formulations intended for pharmaceutical, medical, cosmetic, or agricultural use. The particles that can be prepared by a variety of methods and will preferably comprise a pharmaceutical agent. Pharmaceutical compositions of the present invention can be used to treat a myriad of conditions and can be administered by many routes, including intravenous, intramuscular, subcutaneous, intrathecal, subdural, intracameral, intracerebral, intralesional, topical, oral, buccal, rectal, transcutaneous, pulmonary, and nasal.
The purpose of this study is the creation, implementation, and analysis of a seizure action plan, an intervention aimed to guide daily medication use, outline pre-hospital seizure first aide and rescue medication use, and direct emergency personnel in patients' individualized status epilepticus medication algorithm, with implementation through the electronic medical record. After creation of the action plan, the primary neurologist and patient/caregiver will create a patient-specific plan. The action plan will be reviewed and updated as necessary at each regularly scheduled primary neurology clinic visit. Two studies will aim at analyzing the effectiveness of this intervention. A prospective observational cohort study of patient care process and outcomes 18 months before and 18 months after initiation of seizure action plan will analyze patients with status epilepticus requiring hospital admission and/or status epilepticus that occurs during admission at BCH and measure rescue medication prescription and application patterns, timeliness of medication administration during SE, use of appropriately dosed AEDs, rate of intubation, significant hypotension, allergic reaction, and other adverse events, and hospital length of stay and rate of ICU admissions. A second prospective observational cohort study of patient outcome variables 18 months before and 18 months after initiation of a seizure action plan obtained through parent-reported ICISS (Integrated Clinical Information Sharing System)/Trivox data, a web-based platform for tracking symptoms and response to therapy, will measure rescue medication prescription and application patterns, interval seizure frequency, effect on patient and parent quality of life, parent knowledge of AED regimen, and parent self-reported medication adherence.
A girl in middle childhood was referred to the paediatric surgical team with acute colicky abdominal pain and bile-stained vomiting. This was preceded by a viral illness. Investigations revealed raised inflammatory markers, and imaging of the abdomen demonstrated ileal and jejunal thickening. Concerns were raised regarding whether she had inflammatory bowel disease. Endoscopy revealed gastritis and duodenitis, and colonoscopy was unremarkable. Video capsule endoscopy demonstrated ulcers in the jejunum and ileum.On day 8 of admission, she developed a symmetrical purpuric rash over both ankles leading to the diagnosis of Henoch-Schonlein-related ileitis. Multidisciplinary team working led to appropriate management of the patient and avoided surgery. Video capsule endoscopy enabled visualisation of the small bowel. She was managed with 5 days of methylprednisolone followed by oral steroids. She made a good recovery with no sequelae. This case highlighted that terminal ileitis is a rare complication of IgA vasculitis with a good prognosis.
The present invention is aimed at providing a dry powder inhalation with minimal adhesive-agglomerative property during storage and with a good inhalation behavior for a pharmaceutically active ingredient, and is a dry powder inhalation wherein at least an active ingredient is adhered to the surface of a carrier particle comprised of erythritol and/or trehalose. It is also a dry powder inhalation wherein at least S-36496 and/or Pralmorelin dihydrochloride is adhered to the surface of the carrier particle. It is further a dry powder inhalation wherein at least an active ingredient and a surface modifier are adhered to the surface of the carrier particle. It is also a preparation method of these. Said dry powder inhalation may be applied to the capsules for use in an inhaler device. In addition to the achievement of above objectives, the present invention provides a dry powder inhalation with improved taste in inhalation or with reduced discomfort in the oral cavity and the throat, and a preparation method for enabling an easy preparation thereof without complicated processes.
PROBLEM TO BE SOLVED: To obtain an anti methicillin-resistant Staphylococcus aureus(anti- MRSA) active composition, having anti-MRSA activity, suppressing β-lactam agent resistance, inducing sensitivity by including apigenin being a flavone derivative contained in Scutellaria barbata D. Don as an active ingredient. SOLUTION: The composition contains apigenin of the formula as an active ingredient. Apigenin is obtained, for example, by extracting Scutellaria barbata D. Don with ethanol, adding an ether to the extract, subjecting the extract to liquid-liquid partitioning extraction, then subjecting the ether extracted fraction to silica gel chromatography and separating and purifying a fraction having antimicrobial activity. Preferably apigenin is used together with a β-lactam-based antibiotic to enhance antimicrobial actions. For example, methicillin, oxacillin, cephalothin, et., may be cited as the β-lactam-based antibiotic substance. A flavone derivative such as quercetin, sakuranetin, etc., can be used as the active ingredient for an anti-MRSA active medicine composition.
The subjects were recruited consecutively from the list of patients seeking care for periodontal problems at the Department of Periodontology of the Faculty of Dental Medicine, Al Azhar University, Cairo, Egypt, between March 2012 to December 2012. The criteria implemented for patient inclusion were: 1) no systemic diseases which could influence the outcome of the therapy; 2) good compliance with the plaque control instructions following initial therapy; 3) teeth involved were all vital with score 0 mobility ; 4) each subject contributed matched pairs of two or three walled intrabony interproximal defects in premolar or molar teeth 5) the selected 2- or 3-wall intrabony defect depth ranged from 3-5 mm as detected in diagnostic periapical radiographs; 6) selected pocket depth (PD) ≥ 6 mm and clinical attachment level (CAL) ≥ 5 mm at the site of endosseous defect four weeks following initial cause-related therapy 7) endosseous radiographic defect angle ≤55 and ≥15 8) availability for the follow-up and maintenance program; 9) absence of periodontal treatment for the previous year; 10) absence of systemic medication or antibiotic treatment for the previous 6 months; 11) absence of a smoking habit and 12) absence of occlusal interferences. Pregnant females were excluded from participating in the study. Patients were also excluded from the study if they presented with opened interproximal contact, or inadequate compliance with the oral hygiene maintenance schedule. The experimental protocol was approved by the Ethical Committee of El Azhar University (OMD - 45 - 2012, clinical trial registration number: Al Azhar University 22-31). Research procedures were explained to all patients and they agreed to participate in the study and signed the appropriate informed consent form of Al Azhar University.
N-Acetyl glucosamine (GInNAC). Given orally (1g three times daily) for 14 days, gradually increased from 0.5g to avoid osmotic diarrhoea, in addition to standard care following WHO guidelines for management of SAM.